Drugs / Glimepiride
Glimepiride
also known as
Amaryl · HOE490 · Amaryl - glimepiride · GLIM · glimepiride (Amaryl) · Glimepirida · Glimepiride component of avandaryl · Glimepiride component of duetact · +3 more
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Avaglim | — | 2006-06-27 | europa.eu ↗ |
| Label expansions (3) | US (FDA) | AMARYL | — | 1999-02-24 – 2005-11-28 | fda.gov ↗ |
| Approved | US (FDA) | AMARYL | — | 1995-11-30 | fda.gov ↗ |
Trials 70 · started per year
today
US approved 1995
EU approved 2006
1
3
4
3
2
3
2
2
4
7
4
4
7
4
1
4
2
6
1
1
1
1
1
2
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 117 trials · 1 met primary · 1 missed | ||||||
| Phase 1 | NCT06644404 | Oct → Dec 2024 overdue | — | Daewoong Pharmaceutical Co. LTD. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03009513 | Jan → May 2017 | diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02954822 | Nov 2016 → Jan 2017 | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02395237 | May 2015 | — | Pharmaceutical Research Unit, Jordan | Withdrawn | No outcome recorded |
| Phase 1 | NCT01768455 | Feb → Apr 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01614769 | Jul 2012 → Jan 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 1 | NCT01496443 | Jan → May 2012 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01437800 | Jan 2011 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT01437813 | Jan 2011 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT01133431 | May → Jun 2010 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01302158 | Dec 2009 → Apr 2010 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT02172261 | Apr → Jun 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00934323 | Oct → Nov 2008 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00934817 | Mar → May 2007 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00648362 | Nov 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00650533 | Nov → Dec 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00835172 | Mar 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT01425580 | Jan 2012 → Aug 2016 | congestive heart failure, type 2 diabetes mellitus | Thomas Nystrom | Completed | No outcome recorded |
| Phase 320 trials · 4 met primary | ||||||
| Phase 3 | NCT07288749 | Jan 2026 → Dec 2030 expected | heart failure, type 2 diabetes mellitus | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04841096 | Mar 2023 → Mar 2024 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT03060980 | Mar 2017 → Jan 2018 | type 2 diabetes mellitus | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT02484209 | Feb → Oct 2016 | diabetes mellitus | Diabetes Frail Ltd | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02419612 | Aug 2015 → Aug 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT01863667 | Jul 2013 → Apr 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01699932 | Sep 2012 → Apr 2014 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01459809 | Feb 2012 → Jan 2014 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01477853 | Oct 2011 → Dec 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01296412 | Mar 2011 → Feb 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01243424 | Nov 2010 → Aug 2018 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT00614120 | Jan 2008 → Feb 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00770952 | Dec 2006 → Dec 2008 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00437554 | Aug 2006 → Jul 2007 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00151697 | May 2005 → ? | type 2 diabetes mellitus | Rijnstate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00353691 | Oct 2002 → Nov 2004 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00783744 | Dec 2001 → Aug 2003 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00044447 | May 2001 → Sep 2002 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00379769 | Apr 2001 → Dec 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00032487 | Dec 2000 → May 2008 | type 2 diabetes mellitus | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 427 trials · 1 met primary · 3 missed | ||||||
| Phase 4 | NCT05386186 | Jan 2022 → Oct 2023 | type 2 diabetes mellitus | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04287387 | Mar 2020 → Mar 2021 | type 2 diabetes mellitus | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03693560 | Oct 2018 → Sep 2019 | coronary artery disorder, type 2 diabetes mellitus | Damanhour University | Completed | No outcome recorded |
| Phase 4 | NCT03804411 | Aug 2017 → Mar 2020 | type 2 diabetes mellitus | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Unknown | No outcome recorded |
| Phase 4 | NCT03118713 | Apr 2017 → Dec 2018 | type 2 diabetes mellitus | Astellas Pharma Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04237493 | Feb → Jul 2017 | type 2 diabetes mellitus | University of Jordan | Completed | No outcome recorded |
| Phase 4 | NCT02973477 | Jan 2017 → Aug 2019 | cardiovascular disorder, type 2 diabetes mellitus | University of Michigan | Completed | Missed primary |
| Phase 4 | NCT02373865 | Sep 2015 → Jan 2017 | type 2 diabetes mellitus | GWT-TUD GmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01890629 | May 2013 → Aug 2014 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01812122 | Mar 2013 → Aug 2015 | type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01660386 | Jul → Dec 2012 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01341717 | Feb 2012 → May 2014 | type 2 diabetes mellitus | Jothydev's Diabetes and Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT01204580 | Dec 2010 → Mar 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01144728 | May → Dec 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00957060 | Jul 2009 → Oct 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00913367 | May 2009 → Nov 2010 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00908921 | Apr 2009 → Sep 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00941161 | Feb 2009 → May 2010 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 4 | NCT00700856 | Sep 2008 → Dec 2018 | cardiovascular disorder, type 2 diabetes mellitus | Italian Society of Diabetology | Unknown | Missed primary |
| Phase 4 | NCT00708578 | May 2008 → Dec 2009 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01429818 | Jul 2007 → Jan 2008 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 4 | NCT00318656 | Nov 2005 → Oct 2007 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | Missed primary |
| Phase 4 | NCT02142309 | Oct 2005 → Oct 2015 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT00619697 | Dec 2003 → Mar 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 4 | NCT00642915 | Jun 2003 → Jul 2004 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00633425 | Oct 2002 → Oct 2003 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00133718 | Jan 2002 → Apr 2006 | type 2 diabetes mellitus | Asker & Baerum Hospital | Completed | Mixed |
| Phase not applicable5 trials | ||||||
| — | NCT07589387 | May 2026 → Apr 2029 expected | diabetes mellitus | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT02443922 | Jun → Dec 2015 | type 2 diabetes mellitus | Foundation for the National Institutes of Health | Unknown | No outcome recorded |
| — | NCT02026310 | Jan 2014 → Nov 2015 | type 2 diabetes mellitus | Qifu Li | Completed | No outcome recorded |
| — | NCT00978263 | Feb 2009 → Dec 2011 | diabetes mellitus | Chongqing Medical University | Completed | No outcome recorded |
| — | NCT00608179 | Aug 2002 → Sep 2004 | type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
| Comparator or background therapy149 trials | ||||||
| Phase 1 | NCT02956044 Comparator | Nov 2016 → Mar 2017 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT01703286 Comparator | Oct 2012 → Jan 2014 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT01725672 Comparator | Sep 2012 → Aug 2013 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00842556 Comparator | Mar → May 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00562250 Comparator | May → Aug 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Show all 149 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 22
| Date | Issuer | Release |
|---|---|---|
| 2021-03-10 | Dong-A ST Co., Ltd. | Results 동아ST, ‘슈가논’ 심혈관계 안전성 연구 결과 SCI급 국제학술지 게재 donga-st.com ↗
연구 결과 에보글립틴은 설포닐유레아(Sulfonylurea, SU) 제제인 글리메피리드 대비 심혈관계 사건 누적 발생률이 33%, 뇌혈관계 사건 누적 발생률이 59%로 유의성있게 낮은 결과를 보였으며 협심증, 심부전, 일과성 허혈성 발작의 위험 증가와는 유의한 연관성을 보이지 않았다. |
| 2019-06-10 | Eli Lilly and Company | Results Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta® lilly.com ↗
Tradjenta was similar to glimepiride in the secondary endpoint of 3P-MACE plus hospitalization for unstable angina (4P-MACE) (13.2% for Tradjenta versus 13.3% for glimepiride). |
| 2019-02-14 | Eli Lilly and Company | Results Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride lilly.com ↗ |
| 2015-12-01 | Eli Lilly and Company | Results New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) is Effective as Add-on Treatment to Sulfonylurea lilly.com ↗
New data from a completed Phase 3 trial show Trulicity® (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering hemoglobin A1c (A1C) from baseline after 24 weeks of treatment. |
| 2013-06-24 | GlaxoSmithKline | Results GSK announces data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes gsk.com ↗
At Week 104, the reduction in HbA1c was statistically significant in the albiglutide group compared to those treated with placebo (-0.9%; p<0.0001), sitagliptin (-0.4%; p=0.0001), or glimepiride (-0.3%; p=0.003). |
| 2013-06-23 | Janssen Research & Development, LLC | Results Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults with Type 2 Diabetes jnj.com ↗
Results of a second Phase 3 study, also in adult patients taking metformin, showed greater improvements in blood glucose control with 300 mg INVOKANA™ and similar improvements with 100 mg INVOKANA™ compared to another commonly prescribed therapy, glimepiride, over a period of 104 weeks. |
| 2013-06-22 | Eli Lilly and Company | Results Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced lilly.com ↗
In a separate exploratory analysis of two-year data from a phase III trial comparing linagliptin to glimepiride, fewer people treated with the DPP-4 inhibitor linagliptin versus the sulfonylurea glimepiride experienced hypoglycemia (7.5 percent vs. 36.1 percent; p < 0.0001). |
| 2013-06-22 | Eli Lilly and Company | Results New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA lilly.com ↗
Patients treated with linagliptin had a lower rate of hypoglycemia compared to those treated with glimepiride. |
| 2013-06-11 | Eli Lilly and Company | Results Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations on Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions® lilly.com ↗
Regardless of the degree of glycemic control, linagliptin (LINA) has lower hypoglycemia risk than all doses of glimepiride (GLIM) at all time points over a 2-year trial |
| 2012-06-09 | Eli Lilly and Company | Results Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company present new linagliptin data at American Diabetes Association's 72nd Scientific Sessions® lilly.com ↗
After 104 weeks of treatment, both linagliptin and glimepiride reduced mean A1C levels by 0.6 percent from baseline (baseline: 7.2 percent linagliptin, 7.3 percent glimepiride) and 76 percent of patients in both groups achieved target A1C < 7 percent. |
| 2011-12-08 | Bristol-Myers Squibb | Results New Data Show Investigational Compound Dapagliflozin When Added to Glimepiride Maintained Reductions in Blood Sugar Levels in Adults with Type 2 Diabetes Over 48 Weeks of Treatment bms.com ↗
In addition to maintaining reductions in blood sugar levels, the 48-week study reported that patients taking dapagliflozin added to glimepiride maintained reductions in fasting plasma glucose levels (FPG), post-prandial glucose (PPG) and total body weight. |
| 2011-06-24 | Eli Lilly and Company | Results Two-Year Data Comparing Cardiovascular Events with Linagliptin and the Sulfonylurea, Glimepiride, Presented as Late-Breaking Poster at ADA lilly.com ↗
twice as many patients taking glimepiride (26 patients) experienced CV events compared to those taking linagliptin (12 patients), demonstrating a 50 percent reduction in relative risk for the combined CV endpoint |
| 2011-06-20 | Eli Lilly and Company | Results Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in More Than 25 Presentations at the 71st American Diabetes Association Scientific Sessions lilly.com ↗
Linagliptin has Improved Safety and Similar Efficacy to Glimepiride over 2 Years in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin |
| 2010-11-17 | Eli Lilly and Company | Results Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia® lilly.com ↗
In the study, BYETTA was associated with a lower incidence of CVD-related events than insulin, thiazolidinediones (TZDs) and sulfonylureas and a comparable incidence versus metformin and Januvia® (sitagliptin). |
| 2010-09-20 | AstraZeneca | Results 24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults with Type 2 Diabetes Mellitus astrazeneca.com ↗
More people taking dapagliflozin and glimepiride were able to achieve a target HbA1c of less than 7% compared to patients taking glimepiride alone. |
| 2010-09-20 | Bristol-Myers Squibb | Results 24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults with Type 2 Diabetes Mellitus bms.com ↗
More people taking dapagliflozin and glimepiride were able to achieve a target HbA1c of less than 7% compared to patients taking glimepiride alone. |
| 2008-09-08 | Bristol-Myers Squibb | Results ONGLYZA(TM) (saxagliptin) Demonstrated Significant Improvements Across Key Measures of Glucose Control When Added to a Sulfonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes bms.com ↗
The addition of saxagliptin to SU or TZD was well tolerated over the course of the studies, and significantly more people were able to achieve target A1C of less than 7 percent versus the comparators. |
| 2007-12-11 | Novo Nordisk A/S | Results Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight novonordisk.com ↗
At both doses tested, liraglutide provided statistically significantly better glucose control than glimepiride. |
| 2005-10-07 | Perrigo Company | Regulatory Perrigo Company Receives Final Approval For Glimepiride Tablets perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced that through a partnership with InvaGen Pharmaceuticals, it has received final approval from the U.S. Food and Drug Administration (FDA) to market Glimepiride Tablets, 1 mg, 2 mg and 4 mg. |
| 2005-10-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval of Glimepiride Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Glimepiride Tablets, 1 mg, 2 mg and 4 mg. |
| 2005-08-25 | Perrigo Company | Regulatory Perrigo Company Announces Tentative Approval for Glimepiride Tablets perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that, through a partnership with InvaGen Pharmaceuticals, it has received tentative approval from the U.S. Food and Drug Administration (FDA) to market Glimepiride Tablets, 1 mg, 2 mg and 4 mg. |
| 2005-06-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval Of Glimepiride Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Glimepiride Tablets, 1 mg, 2 mg and 4 mg. |
All press releases naming this drug 23 releases
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 224 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glimepiride | “The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients...” NCT02314637 ↗217“The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4...” NCT00379769 ↗ “Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose” NCT01999218 ↗ “Subsequently, patients are assigned to receive either the DPP-4 inhibitor Vildagliptin 50 mg twice daily or the sulfonylurea Glimepiride 2 mg twice daily.” NCT03983551 ↗ “The combination of glimepiride(amaryl) and short-acting insulin (novorapid) is thought to attain glycemic control with a smaller increase in body weight.” NCT00151697 ↗ “glimepiride (starting dose 1 mg/day and up-titrated, based upon patient's self-monitoring of blood glucose results, to a maximum dose of up to 6 mg/day)” PMID 21199268 ↗ Feb 2011 “This Arm will include patients receiving Sulphonylureas (Gliclazide/ Glipizide/ Glimepiride/ Tolbutamide) according to the physician's choice.” NCT06449235 ↗ “Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription” NCT01131182 ↗ “If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.” NCT00978263 ↗ “Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.” NCT01087567 ↗ “OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).” NCT01584232 ↗ |
| Known as | Amaryl | “commercially available formulations of metformin extended release (XR) (GLUCOPHAGE ™ Sustained Release \[SR\]) and glimepiride immediate release (IR) (AMARYL ™).” NCT01725672 ↗9“If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.” NCT00978263 ↗ “AvandiaTM and AmarylTM combine two antidiabetic agents, rosiglitazone maleate and glimepiride.” NCT00131664 ↗ “Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.” NCT00608179 ↗ “Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)” NCT00908921 ↗ “AMARYL (Glimepiride)” NCT01457911 ↗ “Amaryl® Tablets 1 mg” NCT00650533 ↗ |
| Known as | Amaryl - glimepiride | “Amaryl - glimepiride” NCT00576784 ↗1“Amaryl (glimepiride)” NCT01340768 ↗ |
| Known as | GLIM | “twice-daily biphasic insulin aspart 30 (30% soluble and 70% protaminated insulin aspart; BIAsp 30) plus metformin (met) was compared with once-daily insulin glargine (glarg)...” PMID 17115351 ↗ Oct 20061“glimepiride (GLIM)” PMID 32052516 ↗ Mar 2020 |
| Known as | Glimepirida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | glimepiride (Amaryl) | “glimepiride (Amaryl)” NCT00000620 ↗1“glimepiride(amaryl)” NCT00474838 ↗ |
| Known as | Glimepiride component of avandaryl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | Glimepiride component of duetact | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | glimepiride/metformin fixed combination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00913367 ↗ |
| Known as | HOE490 | “Determination of the absolute bioavailability of glimepiride (HOE 490), a new
sulphonylurea.” PMID 1490793 ↗ Nov 19923“Drug: Glimepiride (HOE490)” NCT00924573 ↗ “GLIMEPIRIDE (HOE490)” NCT00957060 ↗ “Glimepiride (HOE490)” NCT01457911 ↗ |
| Known as | Niddaryl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | NSC-759809 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Action | Inhibit | “The cardiovascular protective effect of glimepiride may be related to the EET level increase through sEH inhibition.” PMID 36573717 ↗ Dec 2022 |
| Modality | Small molecule | “Glimepiride and glyburide are both second-generation sulfonlyurea drugs used commonly for treatment of type 2 diabetes.” NCT00608179 ↗ |
| Route | Oral | “Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily” NCT00225264 ↗ |